

2021 ASDR ANNUAL SCIENTIFIC MEETING PROGRAM

THURSDAY 29TH - SATURDAY 31ST JULY 2021



DAY 1
Thursday, 29th July, 1:15pm-6:30pm
SESSION 1: BULLOUS DISEASE 1.15 – 3PM
CHAIRS - DEDEE MURRELL & JOHANNES KERN

TIME	SPEAKERS	TITLE
1.15	KIARASH KHOSROTEHRANI ASDR PRESIDENT AND JOHANNES KERN MEETING CONVENOR	WELCOME AND HOUSEKEEPING
1.25	BLAKE SMITH	INVESTIGATING CLINICAL ANALGESICS IN A MOUSE MODEL OF DOMINANT DYSTROPHIC EPIDERMOLYSIS BULLOSA
1.35	DALE JOBSON	THE COST OF BULLOUS DISEASE
1.38	AROJ MOHAMMED	THE SAFETY OF RITUXIMAB FOR TREATMENT OF AUTOIMMUNE BLISTERING DISEASE: A SYSTEMATIC REVIEW
1.41	JESSICA LILIAN MCCLATCHY	DE-ESCALATION OF ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB) PROTOCOLS IN PEMPHIGUS VULGARIS - A SYSTEMATIC REVIEW
1.44	KATE SIMPSON	ULTRA-LOW DOSE RITUXIMAB IN PEMPHIGUS: A SINGLE CENTRE EXPERIENCE
1.47	ALL	QUESTIONS & ANSWERS SESSION
2.00 KEYNOTE	MASAYUKI AMAGAI	PERIPHERAL TOLERANCE TO DESMOGLEIN3, PEMPHIGUS VULGARIS ANTIGEN
2.30 KEYNOTE	KAISA TASANEN	RISK FACTORS OF BULLOUS PEMPHIGOID

BREAK 3.00 – 3.20

DAY 1
Thursday, 29th July, 1:15pm-6:30pm
SESSION 2: KERATINOCYTE CANCER 3.20 - 4.45
CHAIRS - KIARASH KHOSROTEHRANI & NIKOLAS HAASS

TIME	SPEAKERS	TITLE
3.20	SATORU SUGIHARA	THE ANALYSIS OF THE DRIVER MUTATIONS IN BURN SCAR-RELATED SQUAMOUS CELL CARCINOMA BY WHOLE-EXOME SEQUENCE
3.30	ALI AZIMI	INVESTIGATING PROTEOME CHANGES BETWEEN PRIMARY AND METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA USING MASS SPECTROMETRY
3.40	MICHAEL CANGKRAMA	TARGETING ACTIVIN SIGNALING IN EPITHELIAL SKIN CANCER
3.50	EDWIGE ROY	SUBTYPE SPECIFIC ANALYSES REVEAL INFILTRATIVE BASAL CELL CARCINOMA ARE HIGHLY INTERACTIVE WITH THEIR ENVIRONMENT
4:00	MARIA EDUARDA VILELA	BASAL CELL CARCINOMA: EPIDEMIOLOGICAL ANALYSIS OF A 5-YEAR PERIOD IN A BRAZILIAN CITY WITH A HIGH LEVEL OF SOLAR RADIATION
4.03	ALL	QUESTIONS & ANSWERS SESSION
4.15 KEYNOTE	CATERINA MISSERO	ONCOGENIC PATHWAYS IN CUTANEOUS SQUAMOUS CELL CARCINOMA

BREAK 4.45-5.15

DAY 1
Thursday, 29th July, 1:15pm-6:30pm
SESSION 3: SKIN IMMUNOLOGY 5.15 – 6.30
CHAIR - SUSAN CHRISTO AND JANIN CHANDRA

TIME	SPEAKERS	TITLE
5.15	JANIN CHANDRA	SURVIVAL - ASSOCIATED GENE NETWORKS IN CERVICAL AND HEAD AND NECK CANCERS - A SYSTEMS BIOLOGY APPROACH TOWARDS PERSONALISED THERAPY
5.25	JAMIE KOK	IALGAL LIPIDS ATTENUATE CYTOKINE-MEDIATED INFLAMMATORY SIGNALLING AND TIGHT JUNCTION BARRIER DYSFUNCTION IN HUMAN KERATINOCYTE MODELS.
5.35	YUKI HONDA KEITH	CIRCULATING MAST CELL PROGENITORS MIGRATE TO ALLERGIC SKIN THEN ADAPT LOCALLY
5.45	CHENHAO ZHOU	ANTIGEN NONSPECIFIC INDUCTION OF DISTINCT REGULATORY T CELL STATES IN ONCOGENE-DRIVEN HYPERPROLIFERATIVE SKIN
5.48	ALL	QUESTIONS & ANSWERS SESSION
6.00 KEYNOTE	FLORENT GINHOUX	MAPPING THE SKIN MONONUCLEAR PHAGOCYTE SYSTEM

END OF DAY 1

SESSION 4: MELANOMA BIOLOGY 1.00PM - 2.50PM
CHAIR - HELMUT SCHAIDER & MICHELE TENG

TIME	SPEAKERS	TITLE
1.00 KEYNOTE	SHERI HOLMEN	A HIGH THROUGHPUT MODEL OF MELANOMA
1.30	LOREDANA SPOERRI	PHENOTYPIC MELANOMA HETEROGENEITY IS REGULATED THROUGH CELL-MATRIX INTERACTION-DEPENDENT CHANGES IN TUMOR ARCHITECTURE
1.40	COURTNEY WALLINGFORD	PROTECTIVE EFFECT OF MC1R R/R ON MELANOMA RISK IN MITF E318K CARRIERS IN HIGH-RISK COHORTS
1.50	SAMUEL X TAN	PSTAT5 AS AN IMMUNOREGULATORY PROGNOSTIC MARKER OF CUTANEOUS MELANOMA MORTALITY
2.00	NICOLE SEEBACHER	MELANOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IS DEFINED BY THE CANCER STEM CELL PROFILE
2.10	DAVIDE MOI	REPURPOSING BORTEZOMIB FOR IMPROVED TREATMENT OF MELANOMA BY EXPLOITING IMMUNOGENIC CELL DEATH
2.20	ANNELIESE WILLEMS	LENTIGO MALIGNA RECURRENCE ACCORDING TO FACIAL SUBSITE
2.23	NIKOLAS HAASS	ENVIRONMENTALLY STRESSED DRUG-NAÏVE MELANOMA CELL SUBPOPULATIONS SHARE A MOLECULAR SIGNATURE WITH CELLS UNDERGOING INDUCED DRUG TOLERANCE
2.26	MICHELE TENG	TARGETING CD39 IN MELANOMA
2.36	ALL	QUESTIONS & ANSWERS SESSION

BREAK 2.50 - 3.10

SESSION 5: ARTIFICIAL INTELLIGENCE/IMAGING 3.10 – 4.40
CHAIRS - PETER SOYER & TORI MAR

TIME	SPEAKERS	TITLE
3.10	BRIGID BETZ-STABLEIN	ISIC 2020 CHALLENGE
3.25	CLAIRE FELMINGHAM	SMARTI / READER STUDY
3.40	STEPHEN GILMORE	ADVERSARIAL MACHINE LEARNING IN DERMATOLOGY
3.55	ZONGYUAN GE	AI IN IMAGING SPECIALTIES
4.10	LISA ABBOTT	ETHICAL AND LEGAL CONSIDERATIONS
4.25	ALL	QUESTIONS & ANSWERS SESSION

BREAK 4.40 – 5.00

SESSION 6: INFLAMMATION 5.00 – 6.35PM
CHAIRS - PETER FOLEY & CHRIS GRIFFITHS

TIME	SPEAKERS	TITLE
5.00	GE PENG	ANTIMICROBIAL PEPTIDE HBD-3 IMPROVES THE SKIN BARRIER FUNCTION IN ATOPIC DERMATITIS THROUGH AUTOPHAGY ACTIVATION
5.10	SNEHLATA KUMARI	IMMUNOMODULATORY ROLE OF NF-KB SIGNALLING IN NECROPTOSIS-MEDIATED SKIN INFLAMMATION
5.20	HOLLY ANDERTON	LANGERHANS CELLS ARE AN ESSENTIAL CELLULAR INTERMEDIARY IN SHARPIN DEFICIENT CHRONIC DERMATITIS
5.30	ASOLINA BRAUN	MILESTONES TO A CURE: A PATH TOWARDS UNCOVERING HUMAN LEUKOCYTE ANTIGEN C*06:02-RESTRICTED ANTIGEN TRIGGERS IN PSORIASIS
5.40	SIMRANPREET KAUR	SOX9 ABLATION AMELIORATES SCLERODERMATOUS CHRONIC GRAFT VS HOST DISEASE POST ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANT.
5.50	ANDREW AWAD	THE UTILITY OF USING BLISTER FLUID AS THE DIAGNOSTIC SAMPLE IN EX VIVO APPROACHES TO PATIENTS WITH SEVERE CUTANEOUS ADVERSE REACTIONS - AN EXPLORATORY ANALYSIS
5.53	ALL	QUESTIONS & ANSWERS SESSION
6.05 KEYNOTE	MICHEL GILLIET	NEW INSIGHTS INTO SARS-COV2-INDUCED IMMUNOPATHOLOGY FROM COVID-19 SKIN MANIFESTATIONS.

ASDR BOARD MEETING - 6.35PM – 8.50PM
END OF DAY 2

SESSION 7: WOUND HEALING AND STEM CELLS
CHAIRS - PRITINDER KAUR & ALLISON COWIN

TIME	SPEAKERS	TITLE
8.40 - 9:10		Industry Presentations
	BAZ HAMO	PROPAIRA PRESENTATION - SUNSCREENS OF THE FUTURE
	FRANCIS SHAND	ABBVIE PRESENTATION - OVERVIEW AND DERMATOLOGY FOCUS
	KATE CHURCH AND MEREDITH EDWARDS	BRISTOL MYERS SQUIBB - OVERVIEW & DERMATOLOGY FOCUS
9.10	KAMALADASAN KALIDASAN	RECAPITULATING STRESS IN HARD TO HEAL WOUNDS
9.20	SEEN LING SIM	REGULATION OF ENDOVASCULAR PROGENITORS STEMNESS BY MACROPHAGE PARACRINE ACTIVITY IN WOUND HEALING
9.30	LIFENG KANG	BIOENGINEER OF VASCULARIZED SKIN TISSUE FOR DRUG TESTING IN VITRO
9.40	ALL	QUESTIONS & ANSWERS SESSION
9.50 KEYNOTE	SRIKALA RAGHAVAN	MECHANICAL INSTABILITY OF ADHERENS JUNCTIONS OVERRIDES INTRINSIC QUIESCENCE OF HAIR FOLLICLE STEM CELLS

BREAK 10.20 - 10.40

SESSION 8: HAIR, ADNEXAE AND CLINICAL RESEARCH
CHAIR - ROD SINCLAIR

TIME	SPEAKERS	TITLE
10.40	DEDEE MURRELL	THE ILP PROGRAM AT UNSW AND ITS IMPACT ON DERMATOLOGY RESEARCH IN SYDNEY
10.50	HANNAH GRIBBIN	IMPROVING PAEDIATRIC ECZEMA MANAGEMENT ON THE SUNSHINE COAST: A RETROSPECTIVE AUDIT AND NOVEL RESOURCES
10.53	KATHERINE DARCH	A MODERN CONTEXT FOR AN "OLD" DISEASE? RATES OF POSITIVE AND INDETERMINATE QUANTIFERON-TB GOLD TESTING IN A GROUP OF PSORIASIS PATIENTS TREATED WITH BIOLOGIC AGENTS IN BRISBANE, AUSTRALIA.
10.56	LAUREN THOMAS	REVIEW OF ABORIGINAL ACCESS AND EPIDEMIOLOGY TO AN OUTPATIENT TERTIARY HOSPITAL DERMATOLOGY SERVICE
10:59	FARSHID ETAEE	ASSESSMENT OF QUALITY OF LIFE AND SELF-ESTEEM IN PATIENTS UNDERGOING MINOR FACIAL COSMETIC PROCEDURES
11.02	BLAKE MUMFORD	TRANSPLANT DERMATOLOGY DATABASE USING SYSTEMATIZED NOMENCLATURE OF MEDICINE CLINICAL TERMS
11.05	AKSHAY FLORA	SYSTEMATIC REVIEW: UNRAVELLING THE PATHOGENESIS OF PYODERMA GANGRENOSUM
11.08	DALE JOBSON	PYODERMA GANGRENOSUM STAGES OF HEALING
11.11	AKSHAY FLORA	AN ASSESSMENT OF THE EFFICACY OF RISANKIZUMAB AS A NOVEL TREATMENT FOR SYNOVITIS, ACNE, PUSTULOSIS, HYPEROSTOSIS AND OSTEITIS SYNDROME
11.14	KWA MEI QI	DEVELOPMENT OF A HUMAN SEBACEOUS ORGANOID MODEL AS A NEW PLATFORM FOR STUDYING SEBACEOUS GLAND BIOLOGY AND PATHOPHYSIOLOGY
11.24	ALL	QUESTIONS & ANSWERS SESSION
11.40 KEYNOTE	MANABU OHYAMA	ASSESSING THE ADVANTAGES OF USING HUMAN TISSUE-DERIVED OR IPS CELLS FOR HAIR FOLLICLE BIOENGINEERING
12:10	ALL	PRIZES AND WRAPUP

END OF THE DAY